These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 26961150)

  • 1. Targeted treatment and immunotherapy in leptomeningeal metastases from melanoma.
    Geukes Foppen MH; Brandsma D; Blank CU; van Thienen JV; Haanen JB; Boogerd W
    Ann Oncol; 2016 Jun; 27(6):1138-1142. PubMed ID: 26961150
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The combination of stereotactic radiosurgery with immune checkpoint inhibition or targeted therapy in melanoma patients with brain metastases: a retrospective study.
    Martins F; Schiappacasse L; Levivier M; Tuleasca C; Cuendet MA; Aedo-Lopez V; Gautron Moura B; Homicsko K; Bettini A; Berthod G; Gérard CL; Wicky A; Bourhis J; Michielin O
    J Neurooncol; 2020 Jan; 146(1):181-193. PubMed ID: 31836957
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of New Systemic Treatment and Radiotherapy in Melanoma Patients with Leptomeningeal Metastases.
    Tétu P; Sirven-Villaros L; Cuzzubbo S; Ursu R; Baroudjian B; Delyon J; Nataf F; De Margerie-Mellon C; Allayous C; Lefevre W; Carpentier AF; Lebbé C
    Cancers (Basel); 2020 Sep; 12(9):. PubMed ID: 32947841
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Durable complete remission of leptomeningeal melanoma by intrathecal methotrexate maintained with systemic ipilimumab.
    Dietrich C; Salzmann M; Steinbrecher A; Herbst R; Hassel JC
    Immunotherapy; 2021 Sep; 13(13):1079-1083. PubMed ID: 34259028
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Melanoma brain metastasis presentation, treatment, and outcomes in the age of targeted and immunotherapies.
    Bander ED; Yuan M; Carnevale JA; Reiner AS; Panageas KS; Postow MA; Tabar V; Moss NS
    Cancer; 2021 Jun; 127(12):2062-2073. PubMed ID: 33651913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Leptomeningeal disease from melanoma-Poor prognosis despite new therapeutic modalities.
    Chorti E; Kebir S; Ahmed MS; Keyvani K; Umutlu L; Kanaki T; Zaremba A; Reinboldt-Jockenhoefer F; Knispel S; Gratsias E; Roesch A; Ugurel S; Scheffler B; Schadendorf D; Livingstone E; Meier F; Glas M; Zimmer L
    Eur J Cancer; 2021 May; 148():395-404. PubMed ID: 33789203
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study.
    Long GV; Atkinson V; Lo S; Sandhu S; Guminski AD; Brown MP; Wilmott JS; Edwards J; Gonzalez M; Scolyer RA; Menzies AM; McArthur GA
    Lancet Oncol; 2018 May; 19(5):672-681. PubMed ID: 29602646
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Local Tumor Treatment in Combination with Systemic Ipilimumab Immunotherapy Prolongs Overall Survival in Patients with Advanced Malignant Melanoma.
    Theurich S; Rothschild SI; Hoffmann M; Fabri M; Sommer A; Garcia-Marquez M; Thelen M; Schill C; Merki R; Schmid T; Koeberle D; Zippelius A; Baues C; Mauch C; Tigges C; Kreuter A; Borggrefe J; von Bergwelt-Baildon M; Schlaak M
    Cancer Immunol Res; 2016 Sep; 4(9):744-54. PubMed ID: 27466265
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006).
    Schachter J; Ribas A; Long GV; Arance A; Grob JJ; Mortier L; Daud A; Carlino MS; McNeil C; Lotem M; Larkin J; Lorigan P; Neyns B; Blank C; Petrella TM; Hamid O; Zhou H; Ebbinghaus S; Ibrahim N; Robert C
    Lancet; 2017 Oct; 390(10105):1853-1862. PubMed ID: 28822576
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comprehensive Clinical Trial Data Summation for BRAF-MEK Inhibition and Checkpoint Immunotherapy in Metastatic Melanoma.
    Luke JJ
    Oncologist; 2019 Nov; 24(11):e1197-e1211. PubMed ID: 31064886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survival of patients with metastatic melanoma and brain metastases in the era of MAP-kinase inhibitors and immunologic checkpoint blockade antibodies: A systematic review.
    Spagnolo F; Picasso V; Lambertini M; Ottaviano V; Dozin B; Queirolo P
    Cancer Treat Rev; 2016 Apr; 45():38-45. PubMed ID: 26975020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic factors and treatment options in patients with leptomeningeal metastases of different primary tumors: a retrospective analysis.
    Oechsle K; Lange-Brock V; Kruell A; Bokemeyer C; de Wit M
    J Cancer Res Clin Oncol; 2010 Nov; 136(11):1729-35. PubMed ID: 20204406
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Breast cancer patients with brain metastases or leptomeningeal disease: 10-year results of a national cohort with validation of prognostic indexes.
    Znidaric T; Gugic J; Marinko T; Gojkovic Horvat A; Paulin Kosir MS; Golo D; Ivanetic Pantar M; Ratosa I
    Breast J; 2019 Nov; 25(6):1117-1125. PubMed ID: 31286623
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Investigating the role of immunotherapy in advanced/recurrent female genital tract melanoma: a preliminary experience.
    Indini A; Di Guardo L; Cimminiello C; Lorusso D; Raspagliesi F; Del Vecchio M
    J Gynecol Oncol; 2019 Nov; 30(6):e94. PubMed ID: 31576688
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stereotactic radiosurgery combined with nivolumab or Ipilimumab for patients with melanoma brain metastases: evaluation of brain control and toxicity.
    Minniti G; Anzellini D; Reverberi C; Cappellini GCA; Marchetti L; Bianciardi F; Bozzao A; Osti M; Gentile PC; Esposito V
    J Immunother Cancer; 2019 Apr; 7(1):102. PubMed ID: 30975225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term survival with modern therapeutic agents against metastatic melanoma-vemurafenib and ipilimumab in a daily life setting.
    Lang BM; Peveling-Oberhag A; Faidt D; Hötker AM; Weyer-Elberich V; Grabbe S; Loquai C
    Med Oncol; 2018 Jan; 35(3):24. PubMed ID: 29387968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world efficacy and toxicity of combined nivolumab and ipilimumab in patients with metastatic melanoma.
    Parakh S; Randhawa M; Nguyen B; Warburton L; Hussain MA; Cebon J; Millward M; Yip D; Ali S
    Asia Pac J Clin Oncol; 2019 Feb; 15(1):26-30. PubMed ID: 30426665
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of leptomeningeal metastases: Prognostic factors and associated outcomes.
    Brower JV; Saha S; Rosenberg SA; Hullett CR; Ian Robins H
    J Clin Neurosci; 2016 May; 27():130-7. PubMed ID: 26778048
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Ito K; Teng R; Schöder H; Humm JL; Ni A; Michaud L; Nakajima R; Yamashita R; Wolchok JD; Weber WA
    J Nucl Med; 2019 Mar; 60(3):335-341. PubMed ID: 30413661
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic factors and clinical outcomes in patients with leptomeningeal metastasis from solid tumors.
    Waki F; Ando M; Takashima A; Yonemori K; Nokihara H; Miyake M; Tateishi U; Tsuta K; Shimada Y; Fujiwara Y; Tamura T
    J Neurooncol; 2009 Jun; 93(2):205-12. PubMed ID: 19043775
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.